Advanced Radiation Oncology Department, Cancer Care Center, IRCCS Sacro Cuore Don Calabria Hospital, Via Don Sempreboni 5, 37034, Verona, Negrar, Italy.
Radiation Oncology Department, University of Brescia, Brescia, Italy.
Radiol Med. 2020 May;125(5):491-499. doi: 10.1007/s11547-020-01148-4. Epub 2020 Feb 19.
To evaluate tolerance and biochemical control rates of salvage external beam radiotherapy (EBRT) in patients with local relapse from prostate cancer (PC) after high-intensity focused ultrasound (HIFU) as primary treatment.
Twenty-four patients presented biochemical failure of PC. Salvage EBRT to the residual prostate was performed with moderate hypofractionation schedule (MHRT) in 28 fractions (n = 16) or with extreme hypofractionation schedule (SBRT) in 5 fractions (n = 8) by means of image-guided volumetric modulation arc therapy. In case of MHRT, the median dose was 71.4 Gy, whereas in case of SBRT it was 32.5 Gy.
The median follow-up was 28 months. The median PSA nadir was 0.26 ng/mL. In case of MHRT, the median PSA nadir was 0.15 ng/mL and occurred within a median time of 19 months. In case of SBRT, the median PSA nadir was 0.64 ng/mL and occurred within a median time of 8 months. No G3 higher acute or late toxicity after EBRT was observed. Only three patients presented with G2 acute GI toxicity (actinic proctitis). Twelve patients experienced acute G1 GU toxicity: 8/16 of men treated with MHRT and 4/8 of men treated with SBRT. Complete local control of disease was achieved in 23/24 patients (96%).
Our data confirm the feasibility and the low toxicity of salvage EBRT with both schedules of treatment after HIFU failure. The findings of low acute toxicity and good biochemical control rates are encouraging, but a larger number of patients and a longer follow-up are needed to confirm these results.
评估高强度聚焦超声(HIFU)作为初始治疗后局部复发前列腺癌(PC)患者行挽救性外照射放疗(EBRT)的耐受性和生化控制率。
24 例 PC 生化失败患者接受挽救性 EBRT。16 例患者采用中度超分割方案(MHRT)进行 28 次分割,8 例患者采用超分割方案(SBRT)进行 5 次分割,采用图像引导容积调强弧形治疗。在 MHRT 中,中位剂量为 71.4 Gy,而在 SBRT 中为 32.5 Gy。
中位随访时间为 28 个月。中位 PSA 最低值为 0.26ng/ml。在 MHRT 中,中位 PSA 最低值为 0.15ng/ml,发生于中位时间 19 个月。在 SBRT 中,中位 PSA 最低值为 0.64ng/ml,发生于中位时间 8 个月。EBRT 后无 3 级以上急性或迟发性毒性。仅 3 例患者出现 2 级急性 GI 毒性(放射性直肠炎)。12 例患者出现急性 1 级 GU 毒性:16 例 MHRT 治疗的男性中有 8 例,8 例 SBRT 治疗的男性中有 4 例。24 例患者中有 23 例(96%)获得完全的疾病局部控制。
我们的数据证实了在 HIFU 失败后,采用这两种治疗方案行挽救性 EBRT 的可行性和低毒性。低急性毒性和良好的生化控制率的结果令人鼓舞,但需要更多的患者和更长的随访时间来证实这些结果。